Why the study?
SGLT2 inhibitors were associated with reduced atrial fibrillation hospitalizations, prompting evaluation of their effects on atrial tachy-arrhythmias in CIED patients.
Does SGLT2 inhibitor use reduce atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices?
Population
13 888 consecutive CIED patients at two tertiary medical centers
Comparison
SGLT2i use vs no SGLT2i use
Design
Two-center cohort study with blinded event adjudication and propensity score modeling
Follow-up
Total follow-up of 24 442 patient years
Key result
In patients with cardiac implantable electronic devices, SGLT2i use was associated with a reduced risk of atrial tachy-arrhythmias (HR 0.78; 95% CI 0.70-0.87; p<0.001).
Authors
Loading...
May support arrhythmia reduction with SGLT2i in CIED patients; hypothesis-generating and requires randomized confirmation.
Cohort (n=13,888)
Blinded event adjudication
Yes
Does SGLT2 inhibitor use reduce atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices?
Hazard Ratio: 0.78 (95% CI 0.7–0.87)
p-value: p=<.001
In patients with CIEDs, particularly those with heart failure, SGLT2 inhibitor use is associated with a significant reduction in atrial tachy-arrhythmia burden and all-cause mortality.
Younis et al. (2023) conducted a cohort in Cardiac implantable electronic devices (CIEDs) (n=13,888). Sodium glucose cotransporter 2 inhibitors (SGLT2i) vs. No SGLT2i was evaluated on Total number of atrial tachy-arrhythmias (ATA) (HR 0.78, 95% CI 0.70-0.87, p=<.001). In patients with cardiac implantable electronic devices, SGLT2i use was associated with a reduced risk of atrial tachy-arrhythmias (HR 0.78; 95% CI 0.70-0.87; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: